Don't Get Stuck on the Shoulder: Radiation Oncologists Should Get Into the CAR With T-Cell Therapies
- 1 December 2019
- journal article
- editorial
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 105 (5), 1022-1024
- https://doi.org/10.1016/j.ijrobp.2019.09.005
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyCancer Immunology Research, 2019
- Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaInternational Journal of Radiation Oncology*Biology*Physics, 2019
- CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell LymphomaJournal of Clinical Oncology, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaThe New England Journal of Medicine, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2018
- CD19-directed CAR T cells gain tractionThe Lancet Oncology, 2018
- Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen EscapeMolecular Therapy, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL)Cytotherapy, 2017
- The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells.Cancer Investigation, 2013